AIM ImmunoTech and Shenzhen Smoore Technology announced research agreement to develop, easy-to-use treatment approach for the SARS-CoV-2 Pandemic

,

On Apr. 6, 2020, AIM ImmunoTech announced a Material Transfer and Research Agreement (MTA) with Shenzhen Smoore Technology Limited. The purpose of the MTA is to research in China the efficacy of Smoore’s inhalation delivery device using Ampligen, AIM’s flagship drug, which has been approved for ME/CFS in Argentina and experimental through phase 3 clinical trials in the U.S. AIM believes Ampligen has potential as a prophylactic/early-onset therapeutic against COVID-19, the disease caused by SARS-CoV-2.

Tags:


Source: AIM ImmunoTech
Credit:

LifeScienceHistory.com offers three advertising package options. Each package lnclude at least two digital images for multiple page placements and maximum exposure! Rates range from just $300 to $500 per month.